In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Effect of Gamma Knife Radiosurgery and PD1-Antagonists on Metastatic Melanoma

    Final Number:
    1469

    Authors:
    Nathan Nordmann; Molly E. Hubbard MD; Paul Sperduto; H. Brent Clark MD, PhD; Matthew Allan Hunt MD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting

    Introduction: Stereotactic radiosurgery and chemotherapeutics are used together for treatment of metastatic melanoma, and have been linked to delayed radiation-induced vascular leukoencephalopathy (DRIVL). There have been reports of more intense interactions with new immunotherapeutics targeting programmed cell death 1 receptor (PD1), but their interactions have not been well described, and may result in an accelerated response to GKRS. Here we present data on subjects treated with this combination from a single institution.

    Methods: Records from patients who underwent treatment for metastatic melanoma to the brain with GKRS 2011 to 2016 were reviewed. Demographics, date of brain metastasis diagnosis, cause of death when applicable, immunotherapeutics, and imaging findings were recorded. The timing of both radiation therapy and medications were documented, as well as need for additional surgical intervention. Pathologic specimens were recorded when available.

    Results: A total of 33 subjects (61.8% male) were treated with GKRS, and 25 patients underwent treatment with both GKRS and immunotherapy. Regarding the 13 patients treated with PD1-antagonists, 10 received pembrolizumab and 3 received nivolumab. Seven patients developed changes concerning for progression on subsequent MRI, and two underwent resection, but were not found to have residual or new tumor. All 7 had GKRS within 1 month of starting PD1-antagonists. The others without progression had GKRS 1-3 years prior to starting PD1-antagonists, or after stopping PD1-antagonists.

    Conclusions: This abstract offers descriptive data for patients with metastatic melanoma after being treated with multiple treatments. In this cohort, there appears to be a combined effect of GKRS and anti-PD1 therapies. Our data suggests that to see an accelerated response to GKRS, PD1-antagonists should be administered after GKRS, and within a time window of several months.

    Patient Care: A better understanding of the relationship between gamma knife radiosurgery and immunotherapies could lead to an improvement in treatment algorithms.

    Learning Objectives: To evaluate radiation-induced changes in patients with diagnosis of brain metastasis secondary to malignant melanoma who received treatment with GKRS and PD1-antagonists.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy